0001437749-20-006395.txt : 20200327 0001437749-20-006395.hdr.sgml : 20200327 20200327215802 ACCESSION NUMBER: 0001437749-20-006395 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200325 FILED AS OF DATE: 20200327 DATE AS OF CHANGE: 20200327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rice Michael CENTRAL INDEX KEY: 0001389512 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 20753739 MAIL ADDRESS: STREET 1: C/O BIOLIFE SOLUTIONS, INC. STREET 2: 171 FRONT STREET CITY: OWEGO STATE: NY ZIP: 13827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2020-03-25 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001389512 Rice Michael C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 1 President & CEO Common Stock 2020-03-25 4 A 0 12991 A 178815 D Common Stock 2020-03-25 4 A 0 7056 A 185871 D Common Stock 2020-03-25 4 A 0 28868 A 214739 D Restricted Stock Award 0 2020-03-25 4 A 0 28868 0 A Common Stock 28868 28868 D Restricted Stock Award 0 2020-03-25 4 A 0 34641 0 A Common Stock 34641 34641 D The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus. The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation. The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus. /s/ Michael Rice 2020-03-27